Performance Technologies (PTIX)

• Market cap: $6.17M
• 1 day: 5.57%
• 5 days: -2.42%
• 1 month: -12.5%
• 3 months: -8.78%
• 6 months: -4.17%
• Year to date: -55.71%
• 1 year: -57.41%
• 5 years: -97.43%
• 10 years: -97.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's main compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Employees: 3